ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
30 mars 2021 22h25 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
30 mars 2021 16h05 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
24 mars 2021 07h00 HE
|
ProQR Therapeutics N.V.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)QR-421a observed to be well...
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
17 mars 2021 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
02 mars 2021 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
25 févr. 2021 07h00 HE
|
ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from...
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
16 févr. 2021 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
07 janv. 2021 07h00 HE
|
ProQR Therapeutics N.V.
Top-line results expected H1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands...
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
18 déc. 2020 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
18 nov. 2020 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...